H-Phe-Pro-Arg-OH
CAS No. 37553-80-3
H-Phe-Pro-Arg-OH( ——— )
Catalog No. M40458 CAS No. 37553-80-3
H-Phe-Pro-Arg-OH
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameH-Phe-Pro-Arg-OH
-
NoteResearch use only, not for human use.
-
Brief DescriptionH-Phe-Pro-Arg-OH
-
DescriptionH-Phe-Pro-Arg-OH
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number37553-80-3
-
Formula Weight———
-
Molecular Formula———
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
O-Acetyl-L-serine hy...
O-Acetylserine (OASS) is an acylated amino acid derivative. It is an intermediate in the biosynthesis of the common amino acid cysteine in bacteria and plants. Its presence in humans arises from either microbial metabolism in the gut or through consumption of foods containing OASS.
-
PKR-IN-C16
PKR-IN-C16 is a specific protein kinase (PKR) inhibitor.?PKR-IN-C16 is able to inhibit the autophosphorylation of PKR and unlock the translation blockade induced by PKR in primary neuronal cultures.PKR-IN-C16 binds the ATP-binding site of PKR and blocks autophosphorylation with an IC50 value of 186-210 nM.?
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
Cart
sales@molnova.com